• News
  • BioTech

Zacks picks Qualcomm, DexCom for growth

Zacks Equity Research on Monday cited two San Diego firms as being well-positioned for growth in coming months: Qualcomm Inc. (Nasdaq: QCOM) and DexCom Inc. (Nasdaq: DXCM).

The firm predicted Qualcomm will see some strong business growth in China after China Mobile shifts completely to 4G LTE handsets in June.

“We expect Qualcomm will benefit the most from this decision as the company has the most powerful portfolio of five-mode LTE chipsets developed on its state-of-the-art baseband technology,” Zacks said.

Zacks said DexCom looks “well positioned for a solid gain,” even though it has been overlooked by investors lately. DexCom, which specializes in medical instruments, has narrowed its estimated loss for this year from 13 cents to a loss of 9 cents over recent months. But Zacks said the improvement in projected performance has not yet reflected in its price, which has risen only 2.44 percent.

User Response
0 UserComments

Dexcom Inc.

Company Website

5555 Oberlin Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Chg %Chg
High Low
- 1.27%

Insider Trade Data

Date Insider Shares Type Value
10/20/2015 Balo, Andrew K 4,538 Sell $369,670
10/19/2015 Roper, Jess 7,000 Sell $583,573
10/19/2015 Roper, Jess 6,000 Exchange $58,800
10/15/2015 Gregg, Terrance H 15,000 Sell $1,168,796
10/08/2015 Lister, John 2,750 Sell $211,748

Dexcom Inc. Executive(s):

Terrance Gregg

  • Chief Executive Officer, Director

Kevin Sayer

  • Director, President

Patrick Murphy

  • Assist. General Counsel